Because many human cancers including melanoma and ovarian cancer are IFN-γ and TNF-α-sensitive14, it is possible that TR-CD4 will show additional anti-tumor effects against other cancer cell lines that co-express receptors for IFN-γ and TNF-α. This evidence concerns the gene IFNG and neoplasm.